Physician profile
Andrew L Rose
NPI 1437186129
$7,571.98
in general payments reported to CMS, 2019-2025
42 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,005 · 2020: $308 · 2021: $424 · 2022: $1,025 · 2023: $1,167 · 2024: $243 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797 · Education: $13.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.89 |
| Education | $13.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,625.90 | 2019-2023 | |
| Novo Nordisk INC | $968.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $575.17 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $483.19 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $350.47 | 2019-2023 | Trulicity, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $322.15 | 2019-2022 | |
| Pfizer INC. | $231.58 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $183.08 | 2022 | |
| Merck Sharp & Dohme LLC | $169.22 | 2019-2022 | |
| Alkermes, INC. | $149.75 | 2023-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $122.42 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $100.04 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.55 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $91.28 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $87.28 | 2019-2024 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.